mbiomics
Last verified 2026-06-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $32.4Mattributed |
|---|---|
| Latest round | series-a, $32.4M, 2026-04-28attributed |
| Founded | 2020 |
| Headquarters | Munich |
| Industry | bio |
| Stage | series-a |
| Website | mbiomics.com |
Techbio company developing Live Biotherapeutic Products composed of oral live bacterial strains targeting severe and chronic diseases including melanoma
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-04-28 | series-a | $32.4M | undisclosed |
Detected tech stack
framer sites, hsts, http/3, mongodb, node.js, react 16.13.1, recaptcha
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $32.4M | attributed | rss-feeds named as publisher. No document URL on file. |
| Total raised $32.4M | attributed | rss-feeds named as publisher. No document URL on file. |
| Company existence | self-reported | mbiomics.com, read 2026-06-02 |
| Description | self-reported | mbiomics.com, read 2026-06-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.